These synergic effects are supported by recent literature demonstrating that a combination based on splicing and BCL2 inhibition is effective in other hematological malignancies, including multiple myeloma [72] and chronic lymphocytic leukemia [73]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.